Quadrature Capital’s Utah Medical Products UTMD Stock Holding History

Quadrature Capital’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,321	Closed	-$206K	–	2081
2026 Q1	$206K	Buy	+3,321	New	+$209K	﹤0.01%	1111
2024 Q3	–	Sell	-8,521	Closed	-$574K	–	1411
2024 Q2	$574K	Sell	8,521 -23,789	-74%	-$1.62M	0.01%	618
2024 Q1	$2.29M	Buy	32,310 +20,671	+178%	+$1.55M	0.04%	282
2023 Q4	$985K	Sell	11,639 -1,724	-13%	-$143K	0.02%	446
2023 Q3	$1.16M	Buy	13,363 +7,510	+128%	+$693K	0.02%	385
2023 Q2	$546K	Buy	5,853 +1,805	+45%	+$170K	0.01%	562
2023 Q1	$384K	Buy	+4,048	New	+$372K	0.01%	617
2022 Q2	–	Sell	-6,914	Closed	-$619K	–	980
2022 Q1	$619K	Buy	6,914 +426	+7%	+$39.2K	0.02%	358
2021 Q4	$652K	Buy	+6,488	New	+$662K	0.03%	316

Other funds holding UTMD

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quadrature Capital's UTMD Position: Q2 2026 in Review

Quadrature Capital sold out of Utah Medical Products (UTMD) in Q2 2026, closing a stake of 3,321 shares — an estimated $206K sold.

Quadrature Capital first reported a position in UTMD in Q4 2021 and held it in 9 quarters. The position peaked at $2.29M in Q1 2024. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

Quadrature Capital reported no remaining Utah Medical Products position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 3,321 Utah Medical Products shares in Q2 2026, an estimated $206K.
Quadrature Capital first reported a position in Utah Medical Products in Q4 2021 and held it in 9 quarters.
Quadrature Capital's Utah Medical Products position peaked at $2.29M in Q1 2024.
114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.